API | belantamab mafodotin

belantamab mafodotin (TECVAYLI) Report issue

Biologics mAb ADC Orphan Drug ^FDA Approved ^FDA First in Class Breakthrough Therapy ^FDA Accelerated Approval ^FDA

Active Ingredient History

NOW

Now

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
belantamab mafodotin

More Chemistry

Pharmacology

Mechanisms of Action:
- Tumor necrosis factor receptor superfamily member 17 (Mus musculus) ^UniProt
- Tumor necrosis factor receptor superfamily member 17 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: Monomethylauristatin F
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$6164.4200 - $8152.2200

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (29)

Research & Development (29)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (1)

Multiple Myeloma (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Amyloidosis (Phase 1/Phase 2)

Blood Protein Disorders (Phase 1/Phase 2)

Corneal Diseases (Phase 1/Phase 2)

Hematology (Phase 1/Phase 2)

Immunoglobulin Light-chain Amyloidosis (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 1/Phase 2)

Paraproteinemias (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 38
# of Trial Organizations: 29

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue